RESUMEN
Background: Preserved ratio impaired spirometry (PRISm) has been associated with adverse outcomes and increased transition to other spirometric categories over time. We aimed to examine its prevalence, trajectories over time, and outcomes in a population-based sample from Latin America. Methods: Data were obtained from two population-based surveys of adults from three cities in Latin America (PLATINO study), conducted on the same individuals 5-9 years after their baseline examination. We estimated the frequency of PRISm defined by FEV1/FVC≥0.70 with FEV1 <80%, describing their clinical characteristics, longitudinal transition trajectories over time, factors associated with the transition. Results: At baseline, 2942 participants completed post-bronchodilator spirometry, and 2026 at both evaluations. The prevalence of normal spirometry was 78%, GOLD-stage 1 10.6%, GOLD 2-4 6.5%, and PRISm was: 5.0% (95% CI 4.2-5.8). PRISm was associated with less schooling, more reports of physician-diagnosis of COPD, wheezing, dyspnea, missing days at work, having ≥2 exacerbations in the previous year but without accelerated lung function decline. Mortality risk was significantly higher in PRISm (HR 1.97, 95% CI 1.2-3.3) and COPD GOLD 1-4 categories (HR 1.79, 95% CI 1.3-2.4) compared with normal spirometry. PRISm at baseline most frequently transitioned to another category at follow-up (46.5%); 26.7% to normal spirometry and 19.8% to COPD. The best predictors of transition to COPD were closeness of FEV1/FVC to 0.70, older age, current smoking, and a longer FET in the second assessment. Conclusion: PRISm, is a heterogeneous and unstable condition prone to adverse outcomes that require adequate follow-up.
Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica , Adulto , Humanos , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , América Latina/epidemiología , Espirometría , Pruebas de Función Respiratoria , Prevalencia , Volumen Espiratorio Forzado , Capacidad VitalRESUMEN
BACKGROUND: We aimed to study the adverse outcomes of symptomatic and asymptomatic non-obstructed individuals and those with mild COPD longitudinally in participants from three Latin-American cities. METHODS: Two population-based surveys of adults with spirometry were conducted for these same individuals with a 5- to 9-year interval. We evaluated the impact of respiratory symptoms (cough, phlegm, wheezing or dyspnea) in non-obstructed individuals, and among those classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1, COPD on exacerbation frequency, mortality and FEV1 decline, compared with asymptomatic individuals without airflow obstruction or restriction. RESULTS: Non-obstructed symptomatic individuals had a marginal increased risk of mortality (HR 1.3; 95% CI 0.9-1.94), increased FEV1 decline (-4.5 mL/year; 95% CI -8.6, -0.4) and increased risk of 2+ exacerbations in the previous year (OR 2.6; 95% CI 1.2-6.5). Individuals with GOLD stage 1 had a marginal increase in mortality (HR 1.5; 95% CI 0.93-2.3) but a non-significant impact on FEV1 decline or exacerbations compared with non-obstructed individuals. CONCLUSIONS: The presence of respiratory symptoms in non-obstructed individuals was a predictor of mortality, lung-function decline and exacerbations, whereas the impact of GOLD stage 1 was mild and inconsistent. Respiratory symptoms were associated with asthma, current smoking, and the report of heart disease. Spirometric case-finding and treatment should target individuals with moderate-to-severe airflow obstruction and those with restriction, the groups with consistent increased mortality.
Asunto(s)
Pulmón/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Adulto , Anciano , Asma/epidemiología , Asma/fisiopatología , Progresión de la Enfermedad , Femenino , Volumen Espiratorio Forzado , Humanos , Masculino , México/epidemiología , Persona de Mediana Edad , Pronóstico , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/mortalidad , Factores de Riesgo , Índice de Severidad de la Enfermedad , Fumar/efectos adversos , Fumar/epidemiología , Fumar/fisiopatología , América del Sur/epidemiología , Espirometría , Factores de TiempoRESUMEN
BACKGROUND: Lung-function decline is one of the possible mechanisms leading to Chronic Obstructive Pulmonary Disease (COPD). METHODS: We analyzed data obtained from two population-based surveys of adults (n = 2026) conducted in the same individuals 5-9 years (y) after their baseline examination in three Latin-American cities. Post BronchoDilator (postBD) FEV1 decline in mL/y, as %predicted/y (%P/y) and % of baseline/y (%B/y) was calculated and the influence of age, gender, BMI, baseline lung function, BD response, exacerbations rate evaluated using multivariate models. RESULTS: Expressed in ml/y, the mean annual postBD FEV1 decline was 27 mL (0.22%P, 1.32%B) in patients with baseline COPD and 36 (0.14%P, 1.36%B) in those without. Faster decline (in mL/y) was associated with higher baseline lung function, with significant response to bronchodilators, older age and smoking at baseline, also in women with chronic cough and phlegm, or ≥2 respiratory exacerbations in the previous year, and in men with asthma. CONCLUSIONS: Lung function decline in a population-based cohort did not differ in obstructed and non-obstructed individuals, it was proportional to baseline FEV1, and was higher in smokers, elderly, and women with respiratory symptoms.
Asunto(s)
Volumen Espiratorio Forzado , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Anciano , Estudios de Cohortes , Femenino , Humanos , América Latina , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: A low FEV1/FVC from post-bronchodilator spirometry is required to diagnose COPD. Both the FEV1 and the FVC can vary over time; therefore, individuals can be given a diagnosis of mild COPD at one visit, but have normal spirometry during the next appointment, even without an intervention. METHODS: We analyzed two population-based surveys of adults with spirometry carried out for the same individuals 5-9 years after their baseline examination. We determined the factors associated with a change in the spirometry interpretation from one exam to the next utilizing different criteria commonly used to diagnose COPD. RESULTS: The rate of an inconsistent diagnosis of mild COPD was 11.7% using FEV1/FVC <0.70, 5.9% using FEV1/FEV6 Asunto(s)
Técnicas de Diagnóstico del Sistema Respiratorio
, Enfermedad Pulmonar Obstructiva Crónica/diagnóstico
, Adulto
, Broncodilatadores/farmacología
, Progresión de la Enfermedad
, Femenino
, Volumen Espiratorio Forzado
, Humanos
, Modelos Logísticos
, Masculino
, Persona de Mediana Edad
, Prevalencia
, Modelos de Riesgos Proporcionales
, Enfermedad Pulmonar Obstructiva Crónica/fisiopatología
, Espirometría
RESUMEN
BACKGROUND: Spirometry is the gold standard for diagnosing chronic obstructive pulmonary disease (COPD). Although there are a number of different guideline criteria for deciding who should be selected for spirometric screening, to date it is not known which criteria are the best based on sensitivity and specificity. AIMS: Firstly, to evaluate the proportion of subjects in the PLATINO Study that would be recommended for spirometry testing according to Global initiative for Obstructive Lung Disease (GOLD)-modified, American College of Chest Physicians (ACCP), National Lung Health Education Program (NLHEP), GOLD and American Thoracic Society/European Respiratory Society (ATS/ERS) criteria. Secondly, we aimed to compare the sensitivity, specificity, and positive predictive and negative predictive values, of these five different criteria. METHODS: Data from the PLATINO study included information on respiratory symptoms, smoking and previous spirometry testing. The GOLD-modified spirometry indication criteria are based on three positive answers out of five questions: the presence of cough, phlegm in the morning, dyspnoea, age over 40 years and smoking status. RESULTS: Data from 5,315 subjects were reviewed. Fewer people had an indication for spirometry (41.3%) according to the GOLD-modified criteria, and more people had an indication for spirometry (80.4%) by the GOLD and ATS/ERS criteria. A low percentage had previously had spirometry performed: GOLD-modified (14.5%); ACCP (13.2%); NLHEP (12.6%); and GOLD and ATS/ERS (12.3%). The GOLD-modified criteria showed the least sensitivity (54.9) and the highest specificity (61.0) for detecting COPD, whereas GOLD and ATS/ERS criteria showed the highest sensitivity (87.9) and the least specificity (20.8). CONCLUSION: There is a considerable difference in the indication for spirometry according to the five different guideline criteria. The GOLD-modified criteria recruit less people with the greatest sum of sensitivity and specificity.
Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Espirometría/normas , Femenino , Humanos , América Latina , Masculino , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Sensibilidad y EspecificidadRESUMEN
OBJECTIVE: To determine whether the presence of chronic obstructive lung disease (COPD) and reduction of lung function parameters were predictors of mortality in a cohort. MATERIALS/PATIENTS AND METHODS: Population based cohorts were followed in Montevideo, Santiago and Sao Paulo during 5, 6 and 9 years, respectively. Outcomes included all-cause, cardiovascular, respiratory and cancer mortality; exposures were COPD, forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). Cox regression was used for analyses. Sensitivity, specificity, positive and negative predictive values, receiver operator characteristics curves and Youden's index were calculated. RESULTS: Main causes of death were cardiovascular, respiratory and cancer. Baseline COPD was associated with overall mortality (HRâ=â1.43 for FEV1/FVCAsunto(s)
Volumen Espiratorio Forzado
, Enfermedad Pulmonar Obstructiva Crónica/mortalidad
, Enfermedad Pulmonar Obstructiva Crónica/fisiopatología
, Adulto
, Estudios de Cohortes
, Femenino
, Humanos
, Estimación de Kaplan-Meier
, Masculino
, Persona de Mediana Edad
, Valor Predictivo de las Pruebas
, Modelos de Riesgos Proporcionales
, Enfermedad Pulmonar Obstructiva Crónica/diagnóstico
, Enfermedad Pulmonar Obstructiva Crónica/epidemiología
, Curva ROC
, Espirometría
RESUMEN
ANTECEDENTES: El estudio basal del PLATINO, llevado a cabo entre 2003 y 2005 en 5 ciudades latinoamericanas (São Paulo, Ciudad de México, Montevideo, Santiago, Caracas), mostró una prevalencia elevada de la enfermedad pulmonar obstructiva crónica (EPOC). Métodos/diseño: Se llevó a cabo un estudio de seguimiento en 3 de los 5 centros (Montevideo, Santiago y São Paulo) después de un periodo de 5, 6 y 9 años, respectivamente, con el objetivo de verificar la estabilidad del diagnóstico de EPOC a lo largo del tiempo, la evolución de la enfermedad en cuanto a supervivencia, morbilidad y función respiratoria, y análisis de los biomarcadores genéticos e inflamatorios en sangre. Se añadieron algunas preguntas adicionales al cuestionario original y se obtuvieron los certificados de defunción a partir de los registros oficiales nacionales. RESULTADOS: El trabajo de campo se ha completado en los 3 centros. De las muestras originales de la fase I del PLATINO pudimos localizar y entrevistar al 85,6% en Montevideo, al 84,7% en Santiago y al 77,7% en São Paulo. Los individuos no localizados se caracterizaban por un mayor nivel de estudios en Brasil y era más probable que fueran fumadores actuales en Santiago y São Paulo que en Montevideo. La calidad global de las espirometrías fue ≥ 80% según los criterios de la American Thoracic Society. El número de muertes fue de 71 (Montevideo), 95 (Santiago) y 135 (São Paulo), y se obtuvieron los certificados de defunción a partir de los registros de mortalidad nacionales del 76,1, del 88,3 y del 91,8% de los casos en Montevideo, Santiago y São Paulo, respectivamente. CONCLUSIONES: Este estudio muestra que es posible realizar estudios longitudinales de base poblacional en Latinoamérica, con tasas de seguimiento elevadas y una alta calidad de los datos de espirometría. La idoneidad de los registros de mortalidad nacionales varía en los distintos centros de Latinoamérica
BACKGROUND: The PLATINO baseline study, conducted from 2003-2005 in five Latin American cities (São Paulo, Mexico City, Montevideo, Santiago, Caracas), showed a high prevalence of chronic obstructive pulmonary disease (COPD).Methods/design: A follow-up study was conducted in three out of the five centers (Montevideo, Santiago, and São Paulo) after a period of 5, 6 and 9 years, respectively, aimed at verifying the stability of the COPD diagnosis over time, the evolution of the disease in terms of survival, morbidity and respiratory function, and the analyses of inflammatory and genetic biomarkers in the blood. Some questions were added to the original questionnaire and death certificates were obtained from the national official registries. RESULTS: The fieldwork has been concluded in the three centers. From the original samples in the PLATINO study phase i, we were able to locate and interview 85.6% of patients in Montevideo, 84.7% in Santiago and 77.7% in São Paulo. Individuals who could not be located had higher education levels in Brazil, and were more likely to be current smokers in Santiago and São Paulo than in Montevideo. The overall quality of spirometries was ≥80% according to American Thoracic Society criteria. The number of deaths was 71 (Montevideo), 95 (Santiago) and 135 (São Paulo), with death certificates obtained from the national mortality registries for 76.1%, 88.3% and 91.8% of cases in Montevideo, Santiago and São Paulo, respectively. CONCLUSIONS: This study shows that is possible to perform population-based longitudinal studies in Latin American with high follow-up rates and high-quality spirometry data. The adequacy of national mortality registries varies among centers in Latin America
Asunto(s)
Humanos , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Progresión de la Enfermedad , América Latina/epidemiología , Estudios de Cohortes , Grupos de Población/estadística & datos numéricosRESUMEN
BACKGROUND: The PLATINO baseline study, conducted from 2003-2005 in five Latin American cities (São Paulo, Mexico City, Montevideo, Santiago, Caracas), showed a high prevalence of chronic obstructive pulmonary disease (COPD). METHODS/DESIGN: A follow-up study was conducted in three out of the five centers (Montevideo, Santiago, and São Paulo) after a period of 5, 6 and 9years, respectively, aimed at verifying the stability of the COPD diagnosis over time, the evolution of the disease in terms of survival, morbidity and respiratory function, and the analyses of inflammatory and genetic biomarkers in the blood. Some questions were added to the original questionnaire and death certificates were obtained from the national official registries. RESULTS: The fieldwork has been concluded in the three centers. From the original samples in the PLATINO study phasei, we were able to locate and interview 85.6% of patients in Montevideo, 84.7% in Santiago and 77.7% in São Paulo. Individuals who could not be located had higher education levels in Brazil, and were more likely to be current smokers in Santiago and São Paulo than in Montevideo. The overall quality of spirometries was ≥80% according to American Thoracic Society criteria. The number of deaths was 71 (Montevideo), 95 (Santiago) and 135 (São Paulo), with death certificates obtained from the national mortality registries for 76.1%, 88.3% and 91.8% of cases in Montevideo, Santiago and São Paulo, respectively. CONCLUSIONS: This study shows that is possible to perform population-based longitudinal studies in Latin American with high follow-up rates and high-quality spirometry data. The adequacy of national mortality registries varies among centers in Latin America.
Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Adulto , Anciano , Recolección de Muestras de Sangre , Índice de Masa Corporal , Estudios de Cohortes , Certificado de Defunción , Femenino , Estudios de Seguimiento , Humanos , América Latina/epidemiología , Masculino , Persona de Mediana Edad , Enfermedad Pulmonar Obstructiva Crónica/sangre , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Sistema de Registros , Fumar/epidemiología , Factores Socioeconómicos , Espirometría , Encuestas y Cuestionarios , Población Urbana/estadística & datos numéricos , Circunferencia de la CinturaRESUMEN
BACKGROUND: Several COPD phenotypes have been described; the COPD-asthma overlap is one of the most recognized. The aim of this study was to evaluate the prevalence of three subgroups (asthma, COPD, and COPD-asthma overlap) in the Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) study population, to describe their main characteristics, and to determine the association of the COPD-asthma overlap group with exacerbations, hospitalizations, limitations due to physical health, and perception of general health status (GHS). METHODS: The PLATINO study is a multicenter population-based survey carried out in five Latin American cities. Outcomes were self-reported exacerbations (defined by deterioration of breathing symptoms that affected usual daily activities or caused missed work), hospitalizations due to exacerbations, physical health limitations, and patients' perception of their GHS obtained by questionnaire. Subjects were classified in three specific groups: COPD--a postbronchodilator (post-BD) FEV1/FVC ratio of < 0.70; asthma--presence of wheezing in the last year and a minimum post-BD increase in FEV1 or FVC of 12% and 200 mL; and overlap COPD-asthma--the combination of the two. RESULTS: Out of 5,044 subjects, 767 were classified as having COPD (12%), asthma (1.7%), and COPD-asthma overlap (1.8%). Subjects with COPD-asthma overlap had more respiratory symptoms, had worse lung function, used more respiratory medication, had more hospitalization and exacerbations, and had worse GHS. After adjusting for confounders, the COPD-asthma overlap was associated with higher risks for exacerbations (prevalence ratio [PR], 2.11; 95% CI, 1.08-4.12), hospitalizations (PR, 4.11; 95% CI, 1.45-11.67), and worse GHS (PR, 1.47; 95% CI, 1.18-1.85) compared with those with COPD. CONCLUSIONS: The coexisting COPD-asthma phenotype is possibly associated with increased disease severity.
Asunto(s)
Asma/epidemiología , Hospitalización/estadística & datos numéricos , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Adulto , Anciano , Asma/fisiopatología , Comorbilidad , Femenino , Volumen Espiratorio Forzado/fisiología , Encuestas Epidemiológicas , Humanos , América Latina/epidemiología , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Fenotipo , Prevalencia , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Factores de Riesgo , Índice de Severidad de la Enfermedad , Capacidad Vital/fisiologíaRESUMEN
INTRODUCCIÓN: La enfermedad pulmonar obstructiva crónica (EPOC) se asocia a comorbilidades que influyen en el estado de salud y en el pronóstico de los pacientes. El estudio PLATINO aporta datos sobre comorbilidades autorreportadas y percepción del estado general de salud (EGS) en la EPOC. MÉTODOS: PLATINO es un estudio poblacional, sobre prevalencia de EPOC en 5 ciudades de Latinoamérica. El diagnóstico de EPOC se realizó según el criterio de GOLD (FEV1/FVC < 0,70 post-broncodilatador). Se recogió información sobre las siguientes comorbilidades: cardíaca, hipertensión, diabetes, accidente cerebrovascular (ACV), úlcera y asma. El EGS se evaluó mediante el cuestionario SF-12, con la pregunta: «En general ¿diría usted que su salud es: excelente, muy buena, buena, regular o pobre?». Sumando las comorbilidades, se elaboró un índice de comorbilidad. RESULTADOS: Sobre una población total de 5.314 individuos se realizó diagnóstico de EPOC en 759. Las comorbilidades reportadas en orden decreciente fueron: cualquier tipo de enfermedad cardiovascular, hipertensión, úlcera péptica, enfermedad cardíaca, diabetes, ACV, asma y cáncer de pulmón. Los sujetos con EPOC tuvieron mayor índice de comorbilidad, prevalencia de cáncer de pulmón (p < 0,0001) y asma (p < 0,0001), así como mayor tendencia a hipertensión (p = 0,0652) y ACV (p = 0,0750). Los factores asociados a comorbilidad en EPOC fueron la edad, el índice de masa corporal (IMC) y el género femenino. Con el deterioro del EGS aumenta el número de comorbilidades. CONCLUSIONES: En población no seleccionada los individuos con EPOC presentan más comorbilidades. La edad, el sexo femenino y mayor IMC son los principales factores asociados a comorbilidad en estos pacientes. Independientemente de la condición de EPOC, un mayor número de comorbilidades se asocia a peor EGS (AU)
INTRODUCTION: Comorbidities are common in patients with chronic obstructive pulmonary disease (COPD), and have a significant impact on health status and prognosis. The PLATINO study provides data on self-reported comorbidities and perceived health status in COPD subjects. METHODS: PLATINO is a population-based study on COPD prevalence in five Latin American cities. COPD diagnosis was defined by GOLD criteria (FEV1/FVC<0.70 post-bronchodilator). Information was collected on the following comorbidities: heart disease, hypertension, diabetes, cerebrovascular disease, peptic ulcer and asthma. Health status was evaluated using the SF-12 questionnaire, derived from the question: "In general, would you say your health is excellent, very good, good, fair or poor?" A simple comorbidity score was calculated by adding the total number of comorbid conditions. RESULTS: Of a total population of 5314 individuals, 759 had COPD. Reported comorbidities by decreasing frequency were: any cardiovascular disease, hypertension, peptic ulcer, heart disease, diabetes, cerebrovascular disease, asthma and lung cancer. COPD patients had a higher comorbidity score and prevalence of lung cancer (P<0.0001) and asthma (P<0.0001), as well as a higher tendency to have hypertension (P=0.0652) and cerebrovascular disease (P=0.0750). Factors associated with comorbidities were age, body mass index (BMI) and female gender. The number of comorbidities increased as the health status deteriorated. CONCLUSIONS: In the PLATINO population-based study, COPD individuals had an increased number of comorbidities. Age, female gender and higher BMI were the factors associated with comorbidity in these patients. Comorbid conditions were associated with impaired health status, independently of the COPD status (AU)
Asunto(s)
Humanos , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Perfil de Impacto de Enfermedad , Comorbilidad , Estado de Salud , Distribución por Edad y Sexo , Factores de RiesgoRESUMEN
QUESTION: A 6-second spirometry test is easier than full exhalations. We compared the reliability of the ratio of the Forced expiratory volume in 1 second/Forced expiratory volume in 6 seconds (FEV1/FEV6) to the ratio of the FEV1/Forced vital capacity (FEV1/FVC) for the detection of airway obstruction. METHODS: The PLATINO population-based survey in individuals aged 40 years and over designed to estimate the prevalence of post-Bronchodilator airway obstruction repeated for the same study participants after 5-9 years in three Latin-American cities. RESULTS: Using the FEV1/FVCAsunto(s)
Enfermedad Pulmonar Obstructiva Crónica/diagnóstico
, Enfermedad Pulmonar Obstructiva Crónica/fisiopatología
, Pruebas de Función Respiratoria/métodos
, Ciudades/estadística & datos numéricos
, Femenino
, Estudios de Seguimiento
, Volumen Espiratorio Forzado
, Humanos
, América Latina/epidemiología
, Estudios Longitudinales
, Masculino
, Persona de Mediana Edad
, Prevalencia
, Enfermedad Pulmonar Obstructiva Crónica/epidemiología
, Reproducibilidad de los Resultados
, Espirometría
, Capacidad Vital
RESUMEN
OBJECTIVES: We aimed to describe the distribution of self-reported sleep duration in adults over the age of 40 years and to analyze the associated risk factors, comorbid conditions, and quality of life (QoL). METHODS: Our study was constructed as a cross-sectional population-based study and is part of the PLATINO (Spanish acronym for the Latin American Project for Research in Pulmonary Obstruction) study. It includes data from Mexico City (Mexico), Montevideo (Uruguay), Santiago (Chile), and Caracas (Venezuela). Data from 4533 individuals were analyzed using a single questionnaire entitled, PLATINO, which was designed to collect data on self-reported sleep symptoms. Spirometry also was performed in accordance with international standards. All statistical analyses took the study design into consideration with adjustments for each city. RESULTS: The prevalence of subjects who reported sleeping <7h was 38.4%, ≥ 7 to <9h was 51.4%, and ≥ 9h was 10.2%. In the multivariate analysis, individuals with shorter sleep duration had higher frequencies of insomnia, increased forced expiratory volume in one second in liters and percentage/forced vital capacity in liters (FEV1/FVC) of predicted ratios, and a higher presence of coughing and phlegm. The main risk factor associated with longer duration of sleep was the number of comorbidities. CONCLUSIONS: Self-reported sleep duration discriminated among groups that differed in sleep-related symptoms, respiratory symptoms, QoL and comorbid conditions.
Asunto(s)
Percepción , Calidad de Vida , Trastornos del Inicio y del Mantenimiento del Sueño/epidemiología , Sueño , Enfermedades Cardiovasculares/epidemiología , Comorbilidad , Estudios Transversales , Diabetes Mellitus/epidemiología , Femenino , Volumen Espiratorio Forzado , Gastritis/epidemiología , Humanos , Enfermedades Pulmonares/epidemiología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Prevalencia , Factores de Riesgo , Autoinforme , Capacidad VitalRESUMEN
INTRODUCTION: Comorbidities are common in patients with chronic obstructive pulmonary disease (COPD), and have a significant impact on health status and prognosis. The PLATINO study provides data on self-reported comorbidities and perceived health status in COPD subjects. METHODS: PLATINO is a population-based study on COPD prevalence in five Latin American cities. COPD diagnosis was defined by GOLD criteria (FEV1/FVC<.70 post-bronchodilator). Information was collected on the following comorbidities: heart disease, hypertension, diabetes, cerebrovascular disease, peptic ulcer and asthma. Health status was evaluated using the SF-12 questionnaire, derived from the question: «In general, would you say your health is excellent, very good, good, fair or poor?¼. A simple comorbidity score was calculated by adding the total number of comorbid conditions. RESULTS: Of a total population of 5314individuals, 759 had COPD. Reported comorbidities by decreasing frequency were: any cardiovascular disease, hypertension, peptic ulcer, heart disease, diabetes, cerebrovascular disease, asthma and lung cancer. COPD patients had a higher comorbidity score and prevalence of lung cancer (P<.0001) and asthma (P<.0001), as well as a higher tendency to have hypertension (P=.0652) and cerebrovascular disease (P=.0750). Factors associated with comorbidities were age, body mass index (BMI) and female gender. The number of comorbidities increased as the health status deteriorated. CONCLUSIONS: In the PLATINO population-based study, COPD individuals had an increased number of comorbidities. Age, female gender and higher BMI were the factors associated with comorbidity in these patients. Comorbid conditions were associated with impaired health status, independently of the COPD status.
Asunto(s)
Estado de Salud , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Adulto , Anciano , Asma/epidemiología , Trastornos Cerebrovasculares/epidemiología , Comorbilidad , Estudios Transversales , Diabetes Mellitus/epidemiología , Femenino , Indicadores de Salud , Cardiopatías/epidemiología , Humanos , Hipertensión/epidemiología , América Latina/epidemiología , Masculino , Persona de Mediana Edad , Úlcera Péptica/epidemiología , Prevalencia , Pronóstico , Espirometría , Encuestas y Cuestionarios , Tuberculosis/epidemiología , Población UrbanaRESUMEN
Introducción: para la interpretación de las pruebas de función pulmonar se utilizan valores de referencia (normales) que se comparan con los medidos para detectar alteración funcional. Existen discrepancias entre las ecuaciones en pediatría: un limitado númerode participantes, no disponibles o no comparables debido a que se realizan con otros métodos. Objetivos: medir la capacidad residual funcional(CRF) en niños asmáticos controlados quepresentaron espirometría normal. Analizar por grupos de edad y talla las medidas de dispersión de las distintas variables funcionales (volúmenes y capacidades pulmonares). Métodos:estudio transversal; incluye niños y adolescentes asmáticos controlados (clínica-funcional). Se realizó determinación de CRF por técnica de lavado de nitrógeno (N2) (Easy One ProLab ®) bajo condiciones estandarizadas. Se analizan los datos de dispersión de las variables funcionales estratificadas por cuartiles de talla. Resultados: se estudiaron 86 niños, 49 varones (57%), edad media 11,01 ± 2,46 años. Asmaobesidad en 37,21%. Existe una relación lineal entre la CRF y la talla: por cada aumento en 1 centímetro de la altura hay un aumento de la CRF en 0,23 litros (IC95% 0,19 0,27 L) p= 0,000. Conclusiones: la CRF guarda relación con el tamaño corporal (altura), por tanto es de gran importancia medir estas variables de desarrollo pulmonar desde etapas tempranas hasta la adolescencia, para comprender en términos evolutivos pronósticos de las distintas patologías respiratorias. Estos datos son limitados a una población de asmáticos, sin embargo, son un inicio en la interpretación de resultados, probablemente más representativa que las disponibles en la literatura
Introduction: for the interpretation of pulmonaryfunction tests it is useful the reference values (normalpopulation) that are compared with those measured fordetecting functional disturbance. There arediscrepancies between the equations in pediatrics: alimited number of participants, not available or notcomparable because they are performed with othermethods.Objectives: measure the CRF in controlled asthmaticchildren who had normal spirometry. Analyze by ageand size dispersion measures of functional variables(volumes and lung capacities).Methods: cross-sectional study, including controlledasthmatic children and adolescents(clinical-functional). We carried Functional ResidualCapacity (FRC) by nitrogen washout technique (N2)(Easy One Pro Lab ®) under standardized conditions.We analyze the data of the functional variables stratifiedby quartiles of height.Results: we studied 86 children, 49 men (57%), meanage 11,01 ± 2,46 years. Prevalence of overweight andobesity was 37,21%. A linear relationship existsbetween the CRF and the height: for each 1 centimeterincrease in height there CRF increased by 0,23 liters(95% from 0,19 to 0,27 L) p = 0,000.Conclusions: the CRF is related to body size (height),so it is very important to measure these variables fromearly lung development through adolescence, tounderstand in evolutionary terms the progression ofdifferent respiratory diseases. These data are limited toa population of asthmatics, however, are a start in theinterpretation of results, probably more representativethan those available in the literature.
Asunto(s)
Humanos , Masculino , Adolescente , Femenino , Lactante , Preescolar , Niño , Adulto Joven , Asma/fisiopatología , Tamaño Corporal , Capacidad Residual Funcional , Valores de ReferenciaRESUMEN
BACKGROUND: Although chronic obstructive pulmonary disease (COPD) is mostly related to tobacco smoking, a variable proportion of COPD occurs in never smokers. We investigated differences between COPD in never smokers compared with smokers and subjects without COPD. METHODS: PLATINO is a cross-sectional population-based study of five Latin American cities. COPD was defined as postbronchodilator FEV(1)/FVC <0.70 and FEV(1) <80% of predicted values. RESULTS: Among 5,315 subjects studied, 2278 were never smokers and 3036 were ever smokers. COPD was observed in 3.5% of never smokers and in 7.5% of ever smokers. Never smokers with COPD were most likely older and reported a medical diagnosis of asthma or previous tuberculosis. Underdiagnosis was as common in obstructed patients who never smoked as in ever smokers. CONCLUSIONS: Never smokers comprised 26% of all individuals with airflow obstruction. Obstruction was associated with female gender, older age and a diagnosis of asthma or tuberculosis.
Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Estudios Transversales , Femenino , Humanos , América Latina , Masculino , Persona de Mediana Edad , FumarRESUMEN
Introducción: el aumento de la prevalencia del asma y la obesidad ha llevado a diferentes investigadores a postular que existe una asociación significativa entre ambas entidades. Objetivos: describir y analizar factores asociados al sobrepeso-obesidad en niños y adolescentes asmáticos. Métodos: estudio transversal, con diagnóstico de asma según Global Initiative for Asthma (GINA). Se calculó el IMC y percentiles para edad y sexo (CDC, 2000), definiendo grupos de sobrepeso y obesidad. Resultados: de 559 pacientes, 226 (40,4%) sexo femenino, edad 9,08±2,20 años. La primera crisis se presentó a los 2,36±2,50 años. 23,8% tenían asma intermitente, 33,8% persistente leve, 37,6% moderada y 4,8% eran severos. La relación VEF1/CVF promedio fue de 82,42±9,51%, con cifras de VEF1 97,53±17,38%. El 17,9% tenían sobrepeso y 13,2% obesidad. Las niñas tenían mas sobrepeso y obesidad (OR 1,52, IC95% 1,06-2,19). La primera crisis se presentó antes de los 6 años en 34,1% para el grupo con sobrepeso-obesidad, con un OR = 2,39, IC95% 1,21-4,72. La presencia de crisis en el último año, ajustado por las distintas variables independientes analizadas mostró un OR 1,99, IC95% 1,01-3,95 para sobrepeso-obesidad (p=0,048). Conclusiones: la prevalencia de sobrepeso-obesidad entre los asmáticos estudiados es mayor a la publicada para población general de nuestro país a igual edad. El sexo femenino, las crisis en el último año y el inicio más temprano de la misma mostraron significativamente mayor riesgo de sobre pesoobesidad en los asmáticos estudiados.
Background: the prevalence of asthma and obesity has increased. That has get to speculation they may be related. Objectives: to describe and analyze the factors associated to overweight/obesity in asthmatic children and teenagers. Methods: cross sectional study with asthma diagnosis by Global Initiative for Asthma (GINA). BMI and percentiles for each age and gender were calculated (CDC, 2000) defining overweight and obesity study groups. Results: 559 patients, 226 (40,4 %) were female, aged 9,08 ± 2,20 years. The age of the first asthmatic attack was at 2,36 ± 2,50. 23,8% had intermittent asthma, 33,8% had persistent mild asthma, 37,6% had persistent moderate asthma and 4,8% had severe asthma. In average FEV1/FVC was 82,42 ± 9,51% with FEV1 97,53 ± 17,38%. 17,9% of them were overweight and 13,2% were obese. Girls were more overweight and obese. (OR 1,52 IC95% 1,06-2,19) 34,1% of the overweight/obese group suffered their first asthmatic attack before the age of 6; OR = 2,39 IC95% 1,21- 4,72. The presence of an attack over the past year, adjusted by other independent variables analyzed, showed OR 1,99 IC95% 1,01- 3,95 for overweightobesity (p=0,048).
RESUMEN
BACKGROUND: Acute bronchodilator responsiveness is an area of discussion in COPD. No information exists regarding this aspect of the disease from an unselected COPD population. We assessed acute bronchodilator responsiveness and factors influencing it in subjects with and without airway obstruction in an epidemiologic sample. METHODS: COPD was defined by GOLD criteria (post-bronchodilator FEV(1)/FVC<0.70). In this analysis, subjects with pre-bronchodilator FEV(1)/FVC <0.70 but > or =0.70 post-bronchodilator were considered to have reversible obstruction. Bronchodilator responsiveness after albuterol 200microg was assessed using three definitions: a) FVC and/or FEV(1) increment > or =12% plus > or =200mL over baseline; b) FEV(1)> or =15% increase over baseline; and c) FEV(1) increase > or =10% of predicted value. RESULTS: There were 756 healthy respiratory subjects, 481 subjects with reversible obstruction and 759 COPD subjects. Depending on the criterion used the proportion of person with acute bronchodilator responsiveness ranged between 15.0-28.2% in COPD, 11.4-21.6% in reversible obstructed and 2.7-7.2% in respiratory healthy. FEV(1) changes were lower (110.6+/-7.40 vs. 164.7+/-11.8mL) and FVC higher (146.5+/-14.2mL vs. -131.0+/-19.6mL) in COPD subjects compared with reversible obstructed. Substantial overlap in FEV(1) and FVC changes was observed among the groups. Acute bronchodilator responsiveness in COPD persons was associated with less obstruction and never smoking. CONCLUSIONS: Over two-thirds of persons with COPD did not demonstrate acute bronchodilator responsiveness. The overall response was small and less than that considered as significant by ATS criteria. The overlap in FEV(1) and FVC changes after bronchodilator among the groups makes it difficult to determine a threshold for separating them.
Asunto(s)
Bronquios/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Anciano , Femenino , Volumen Espiratorio Forzado , Humanos , Masculino , Persona de Mediana Edad , Análisis MultivarianteRESUMEN
El asma es la enfermedad crónica más frecuente en la infancia. Sus guías de diagnóstico y tratamiento promueven alcanzar y mantener el control de la enfermedad. Objetivos: determinar el porcentaje de niños con asma controlada aplicando el test de control del asma (ACT infantil), y los niveles de control clínico-funcional (GINA); relacionar estos datos con la espirometría. Metodología: estudio transversal, en niños que concurrieron a la policlínica de neumología en el período marzo 2008 abril 2009.Resultados: de 192 niños, 31,25% presentaron un asma no controlada por ACT infantil. Según GINA 30,46% estaban parcialmente controlados, mientras que el 7,95% no alcanzaron dicho control. El 18,75% tuvieron obstrucción bronquial, y respuesta significativa al salbutamol el 27,10% de los niños; presentando una asociación estadísticamente significativa con el grupo de ACT no controlado (p=0,020). Esta asociación se confirma para los grupos de control clínico por GINA, solamente si obstrucción bronquial es severa (valor p 0,034). Los niños del grupo no controlado por ACT presentaron una probabilidad mayor de tener obstrucción bronquial en la espirometría (OR = 3,13 CI95% 1,50- 6,55), y responder positivamente al salbutamol (OR = 2,51 CI95% 1,19 5,29) El ACT es una herramienta de aplicación en la práctica clínica, que permite diferenciar los niños que no alcanzan un control de la enfermedad y en los que existe una mayor probabilidad de presentar alteraciones de su función pulmonar. Es en ellos que se deberá ajustar la terapéutica.
Asthma is the most common chronic disease in childhood. The goal of asthma guidelines is achieve the control of the disease. Objectives: determine the proportion of children with controlled asthma using the asthma control test (ACT), and the GINA clinical- functional levels. Compare these groups with pulmonary function test. Methodology: cross sectional study assessment asthmatic children between March 2008- April 2009. Results: of 192 children, 31.25% had no control asthma applying ACT instrument. According GINA in 30.46% children, the asthma was partially controlled, while 7.95% can not achieve the control of the disease. 18.75% of them had airflow limitation, and 27.10% significant response to bronchodilator. They had a significant association with the no control ACT group (p= 0,020). This association was present only with the most severe obstructive group among GINA levels (valor p 0,034). The children with ACT no controlled asthma had more probability to have airflow limitation by spirometry (OR = 3.13 CI95% 1.50- 6.55), and significant response to bronchodilator. (OR = 2.51 CI95% 1.19 5.29). The ACT is a tool to apply in clinical practice that recognize a special group with poor control of the disease and more likelihood to present pulmonary function deterioration, so they may receive a specific treatment.
Asunto(s)
Humanos , Lactante , Preescolar , Niño , Asma/diagnóstico , Indicadores de Salud , Pruebas Respiratorias , Encuestas y CuestionariosRESUMEN
BACKGROUND: The PLATINO project was launched in 2002 in order to study the prevalence of chronic obstructive pulmonary disease (COPD) in Latin America. Because smoking is the main risk factor for COPD, detailed data on it were obtained. The aim of this paper was to evaluate the prevalence of smoking and incidence of initiation among middle-aged and older adults (40 years or older). Special emphasis was given to the association between smoking and schooling. METHODS: PLATINO is a multicenter study comprising five cross-sectional population-based surveys of approximately 1,000 individuals per site in Sao Paulo (Brazil), Santiago (Chile), Mexico City (Mexico), Montevideo (Uruguay) and Caracas (Venezuela). The outcome variable was smoking status (never, former or current). Current smokers were those who reported to smoke within the previous 30 days. Former smokers were those who reported to quit smoking more than 30 days before the survey. Using information on year of birth and age of smoking onset and quitting, a retrospective cohort analysis was carried out. Smoking prevalence at each period was defined as the number of subjects who started to smoke during the period plus those who were already smokers at the beginning of the period, divided by the total number of subjects. Incidence of smoking initiation was calculated as the number of subjects who started to smoke during the period divided by the number of non-smokers at its beginning. The independent variables included were sex, age and schooling. RESULTS: Non-response rates ranged from 11.1% to 26.8%. The prevalence of smoking ranged from 23.9% (95%CI 21.3; 26.6) in Sao Paulo to 38.5% (95%CI 35.7; 41.2) in Santiago. Males and middle-aged adults were more likely to smoke in all sites. After adjustment for age, schooling was not associated with smoking. Using retrospective cohort analysis, it was possible to detect that the highest prevalence of smoking is found between 20-29 years, while the highest incidence is found between 10-19 years. Age of smoking onset tended to decline over time among females. CONCLUSION: The prevalence of smoking varied considerably across sites, but was lower among countries with national anti-smoking campaigns.